Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

por McClung, M. R., Zanchetta, J. R., Racewicz, A., Roux, C., Benhamou, C.-L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., Matzkin, E., Boonen, S., Delmas, P.
Publicado 2012

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

por Reginster, J-Y., Kaufman, J-M., Goemaere, S., Devogelaer, J. P., Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M-L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., Roux, C.
Publicado 2011

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

por McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., Recker, R. R.
Publicado 2011